Impedimed
- Short interest
- <0.01%
- −0.33 pp 30d
- as of 2 July 2026
- Reported shorts
- 99.8K
- Shares on issue
- 3.660B
Impedimed (IPD) company profile
Profile, insiders and operations
Company
AI-generated research profile of Impedimed
Impedimed is a global leader in medical technology, specializing in the development and sale of devices using bioimpedance spectroscopy for noninvasive clinical assessment. The company focuses on addressing the challenges of secondary lymphedema, particularly related to breast cancer, through innovative solutions like the SOZO® Digital Health Platform. With operations in the US, Europe, and Australia, Impedimed is committed to improving patient outcomes by setting new standards of care.
Director trades
20 trades recorded
Who owns it
3 substantial holders disclosing 17.52%; held by 0 index ETFs and 3 super fund options tracked
Index funds and super funds
| Fund | Value | Of shares | Of fund | As at |
|---|---|---|---|---|
| HostplusBalanced | $532.6K | n/a | <0.01% | 2026-06-30 |
| RestGrowth | $314.3K | n/a | <0.01% | 2026-06-30 |
| LegalsuperBalanced | $19.0K | n/a | <0.01% | 2026-06-30 |
From ASX substantial holding notices (5% or more), index ETF holdings files and super fund portfolio holdings disclosures. Holders' interests can overlap. How ownership is read.
IPD intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links